CORBUS PHARMACEUTICALS HOLDINGS IN stock forecast: up to 0.18 USD CRBP stock price prognosis

STOCK

Forecast for Tue 29 Nov 2022 price 0.41

CORBUS PHARMACEUTICALS HOLDINGS IN stock price forecast for further price development up to 4.71% (time horizon: 1 day) and price target of 0.18 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) CORBUS PHARMACEUTICALS HOLDINGS IN share price prediction for 2022-11-29 with daily closed price projections

Key Facts

Symbol CRBP 

ISIN US21833P1030 

CUSIP 21833P103


Currency USD


Category Pharmaceutical Preparations

Forecast price change %


News sentiment (1.00)


News <--> Close correlation for next day influence (0.08)

Finance numbers

Revenue 2,822,374.0


Earnings per share -1.13


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

Business 4 1A. Risk Factors 21 1B. Unresolved Staff Comments 50 2. Exhibits, Financial Statement Schedules 65 16. Lenabasum reduces inflammation and limits fibrosis, without immunosuppression. These biologic effects have been demonstrated in cells, animal models, and humans. The DETERMINE Study is fully enrolled with 176 patients. 5 Phase 2 Dermatomyositis Study* *Data on file. A CB1 agonist is a compound that initiates a pharmacologic response when it binds to CB1. Day 0 = start of investigational compound dosing. * Presented at New York Academy of Sciences Webinar on January 27, 2021. About 80,000 individuals in the U.S., Europe and Japan suffer from dermatomyositis. 10,154,986 to the Company with claims covering pharmaceutical compositions of lenabasum. On November 27, 2017, the USPTO issued U.S. Patent No. Similar filings are required in other countries. Orphan product designation must be requested before submitting an NDA. 18 Individual states have also established controlled substance laws and regulations. We believe our relations with our employees are good. Our drug candidates are in various stages of preclinical and clinical testing. Preclinical tests can last years. Similar requirements exist in many of these areas in other countries. Such efforts are subject to significant uncertainty. Conflicts may arise in connection with these indemnification obligations. In order to reduce costs, we may need to develop and implement process improvements. In certain circumstances, violations could lead to criminal proceedings. However, trade secrets are difficult to protect. Litigation may be necessary to defend against these claims. As of December 31, 2020, we had 76 full-time employees. We intend to obtain product liability insurance covering our clinical trials. The lack of an active market may also reduce the fair market value of your shares. Future sales of shares by existing stockholders could cause our stock price to decline. In this event, you could lose some or all of your investment. 51 Our pipeline includes the following programs: 1. In March 2019, Kaken made an upfront payment to us of $27 million. For non-employee options, the expected term is the contractual term. Interest accrues on this loan at an annual rate of 4.89%. Funding may not be available when needed, at all, or on terms acceptable to us. 23.1 Consent of EisnerAmper LLP.* 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.* The Company has also agreed to reimburse Jefferies for certain specified expenses. Actual results could differ from those estimates and changes in estimates may occur. Marketable investments are those with original maturities in excess of three months. At December 31, 2020 and 2019, cash equivalents were comprised of money market funds. The fair value recorded for the derivative liability varies from period to period. The ROU asset also includes any lease payments made and excludes lease incentives. No impairment charges were recorded for the years ended December 31, 2020 and 2019. The standard will be adopted upon the effective date for us beginning January 1, 2021. Interest expense for the year ended December 31, 2020 was approximately $1,126,534. The Company's payment obligations survive the termination of the Investment Agreement. The CFF Warrant expires on January 26, 2025. J7^SK#AC90!?X1Y8R:/[[email protected] MWEC %\'-3[?U]X3^M3?V M98$$"[email protected][S6*/[.L.&-E !_" WHI!WI: "[email protected] HHHH **** "[email protected] H\'2CM0.E ! H^RV__ #PC_P"^ M14FQ?[H_*C8O]T?E0!\']EM_^$

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1595097/000149315221006016/0001493152-21-006016.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

Institutional ownership list is based on filling form information

Holding name Date Amount
PARAMETRIC PORTFOLIO ASSOCIATES LLC 2021-03-31 27262
Point72 Hong Kong Ltd 2021-03-31 1846
HRT FINANCIAL LP 2021-03-31 118862
AdvisorShares Investments LLC 2021-06-30 479453
BRIDGEWAY CAPITAL MANAGEMENT, LLC 2021-03-31 200000

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Concord Street Trust 2021-05-31 88284 Long
Fidelity Salem Street Trust 2021-04-30 667993 Long
Fidelity Concord Street Trust 2021-04-30 11279 Long
iShares U.S. ETF Trust 2021-04-30 1232 Long
BlackRock Funds 2021-04-30 3727 Long

Insider trading for CORBUS PHARMACEUTICALS HOLDINGS IN

CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1769163 Millian Craig Stuart 2022-03-10 BUY Accept Accept Accept Accept
1626003 Cohen Yuval 2022-08-10 BUY Reject Accept Accept Accept

Bollinger Bollinger Bands for CORBUS PHARMACEUTICALS HOLDINGS IN can provide the information where the market is moving based on price information.


CORBUS PHARMACEUTICALS HOLDINGS IN Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.


On-Balance Volume information for CORBUS PHARMACEUTICALS HOLDINGS IN. On-Balance Volume information can be an indicator for bullish or bearish outcome.


Accumulation / Distribution (A/D) indicator information for CORBUS PHARMACEUTICALS HOLDINGS IN. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for CORBUS PHARMACEUTICALS HOLDINGS IN. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for CORBUS PHARMACEUTICALS HOLDINGS IN. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for CORBUS PHARMACEUTICALS HOLDINGS IN. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for CORBUS PHARMACEUTICALS HOLDINGS IN. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for CORBUS PHARMACEUTICALS HOLDINGS IN. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


52W High 52W Low Market Cap

Similar shares


CORBUS PHARMACEUTICALS HOLDINGS IN on Nasdaq

CORBUS PHARMACEUTICALS HOLDINGS IN on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2022-10-05 0.18 2022-10-04 11:02
2022-10-06 0.19 2022-10-04 11:02
2022-10-07 0.19 2022-10-04 11:02
2022-10-10 0.20 2022-10-04 11:02
2022-10-11 0.21 2022-10-04 11:02
2022-10-12 0.21 2022-10-04 11:02
2022-10-13 0.22 2022-10-04 11:02
2022-10-14 0.23 2022-10-04 11:02
2022-10-19 0.25 2022-10-04 11:02
2022-10-20 0.26 2022-10-04 11:02
2022-10-21 0.27 2022-10-04 11:02
2022-10-04 0.18 2022-10-01 10:49
2022-10-17 0.24 2022-10-04 11:02
2022-10-18 0.24 2022-10-04 11:02
2022-10-24 0.27 2022-10-04 11:02
2022-10-25 0.28 2022-10-04 11:02
2022-10-26 0.28 2022-10-04 11:02
2022-10-27 0.29 2022-10-04 11:02
2022-10-28 0.29 2022-10-04 11:02
2022-10-31 0.30 2022-10-04 11:02
2022-11-01 0.30 2022-10-04 11:02
2022-11-02 0.31 2022-10-04 11:02
2022-11-03 0.31 2022-10-04 11:02
2022-11-04 0.32 2022-10-04 11:02
2022-11-07 0.33 2022-10-04 11:02
2022-11-08 0.33 2022-10-04 11:02
2022-11-09 0.34 2022-10-04 11:02
2022-11-10 0.34 2022-10-04 11:02
2022-11-11 0.35 2022-10-04 11:02
2022-11-14 0.35 2022-10-04 11:02
2022-11-16 0.36 2022-10-04 11:02
2022-11-17 0.37 2022-10-04 11:02
2022-11-18 0.37 2022-10-04 11:02
2022-11-15 0.36 2022-10-04 11:02
2022-11-21 0.38 2022-10-04 11:02
2022-11-22 0.38 2022-10-04 11:02
2022-11-23 0.39 2022-10-04 11:02
2022-11-24 0.39 2022-10-04 11:02
2022-11-25 0.40 2022-10-04 11:02
2022-11-28 0.40 2022-10-04 11:02
2022-11-29 0.41 2022-10-04 11:02